Search results for "Pyrazine"

showing 10 items of 325 documents

Coordination nano-space as stage of hydrogen ortho–para conversion

2015

The ability to design and control properties of nano-sized space in porous coordination polymers (PCPs) would provide us with an ideal stage for fascinating physical and chemical phenomena. We found an interconversion of nuclear-spin isomers for hydrogen molecule H 2 adsorbed in a Hofmann-type PCP, {Fe(pz)[Pd(CN) 4 ]} (pz=pyrazine), by the temperature dependence of Raman spectra. The ortho (o)–para (p) conversion process of H 2 is forbidden for an isolated molecule. The charge density study using synchrotron radiation X-ray diffraction reveals the electric field generated in coordination nano-space. The present results corroborate similar findings observed on different systems and confirm …

196Materials scienceHydrogenPyrazine1002chemistry.chemical_elementCatalysissymbols.namesakechemistry.chemical_compoundhydrogen storage porous coordination polymerElectric fieldNano-Moleculelcsh:ScienceMultidisciplinaryCharge density39hydrogen storage porous coordination polymer; structure of absorbed H-2; ortho-para conversion56ChemistrychemistrysymbolsPhysical chemistrylcsh:Qstructure of absorbed H2ortho–para conversionRaman spectroscopyResearch ArticleRoyal Society Open Science
researchProduct

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

2020

Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL). Targeted approaches (i.e. ibrutinib, bortezomib, and lenalidomide) represent the backbone of therapy for relapsed cases. Areas covered: Acalabrutinib is a novel small molecule with a butynamide moiety specifically designed to irreversibly inhibit Bruton tyrosine kinase (BTK), which is more potent and selective than ibrutinib. Relevant publications have been identified through literature searches using the terms 'mantle cell lymphoma' and 'acalabrutinib'. Expert opinion: Aca…

Acalabrutinib; BTK; MCL; therapy; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphoma Mantle-Cell; Protein Kinase Inhibitors; PyrazinesOncologymedicine.medical_specialtyLymphomaAntineoplastic AgentsLymphoma Mantle-Cell03 medical and health scienceschemistry.chemical_compound0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAgammaglobulinaemia Tyrosine KinaseHumansMedicineBruton's tyrosine kinasePharmacology (medical)Protein Kinase InhibitorsLenalidomidePharmacologytherapy.therapybiologyAcalabrutinibbusiness.industryBortezomibStandard treatmentMCLGeneral MedicineMantle-Cellmedicine.diseaseClinical trialchemistryBTKPyrazines030220 oncology & carcinogenesisIbrutinibBenzamidesbiology.proteinAcalabrutinibMantle cell lymphomabusiness030217 neurology & neurosurgerymedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With…

2012

Purpose This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). Patients and Methods Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m2 intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day …

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation AutologousGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleSettore MED/01 - Statistica MedicaBortezomib03 medical and health sciences0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAutologous transplantationSurvival rateMultiple myelomaDexamethasoneAgedBortezomibbusiness.industryHazard ratioTranslational research Immune Regulation [ONCOL 3]Middle Agedmedicine.diseaseBoronic AcidsThalidomide3. Good healthSurgeryThalidomideTransplantationTreatment OutcomeOncologyPyrazines030220 oncology & carcinogenesisFemaleMultiple MyelomabusinessStem Cell Transplantation030215 immunologymedicine.drugJournal of Clinical Oncology
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3‐week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

Adultmedicine.medical_specialtymedicine.drug_classImmunologyIschemiaSystemic SclerosisCalcium channel blockerScleroderma03 medical and health sciences0302 clinical medicineRheumatologyAcetamidesmedicineHumansImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasesIntensive care medicine030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryVascular diseaseRaynaud DiseaseVasospasmmedicine.diseaseSurgeryClinical trialPyrazinesPillOriginal ArticleSugarsbusinessVasodilating AgentArthritis & Rheumatology
researchProduct

Purinoceptor-mediated modulation by endogenous and exogenous agonists of stimulation-evoked [3H]noradrenaline release on rat iris.

1992

To investigate whether endogenous purinoceptor agonists affect the sympathetic neurotransmission in the rat isolated iris, and to classify the purinoceptors modulating exocytotic [3H]-noradrenaline release, we have determined the effect of adenosine receptor antagonists on, and the relative potency of selected agonists in modulating, the field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow. In addition, the apparent affinity constants of 8-phenyltheophylline (8-PT) and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) in antagonizing the prejunctional effects of purinoceptor agonists were estimated. The relatively A1-selective DPCPX 10 and 100 nmol/l increased the evoked [3H]-noradre…

AgonistMalemedicine.medical_specialtyAdenosinemedicine.drug_classIrisBiologyIn Vitro TechniquesSynaptic TransmissionPurinergic AgonistsNorepinephrineAdenosine deaminaseTheophyllineInternal medicinemedicineAnimalsReceptorPharmacologyPurinergic receptorAntagonistReceptors PurinergicRats Inbred StrainsGeneral MedicineAdenosine receptorAdenosineElectric StimulationRatsEndocrinologyPyrazinesXanthinesbiology.proteinmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

CCDC 200157: Experimental Crystal Structure Determination

2004

Related Article: J.Carranza, C.Brennan, J.Sletten, B.Vangdal, P.Rillema, F.Lloret, M.Julve|2003|New J.Chem.|27|1775|doi:10.1039/b301212n

Aqua-(croconato)-(22'-bipyrazine)-copper(ii)Space GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Measurement of interactions between polysaccharides and flavour compounds by exclusion size chromatography: Advantages and limits

1998

Interactions between flavour compounds and polysaccharides have been studied by exclusion size chromatography, the Hummel and Dreyer method. Hydrogen bonding was found between 2-acetyl thiazole and dextrines of different degrees of polymerisation. The number of binding sites and the affinity constant increase by increasing the degree of polymerisation. Hydrogen bonding was also responsible for the interactions between xanthane and 1-octen-3-ol or 2-acetyl pyrazine, with 1 mole of 1-octen-3-ol bound per pentasaccharide repeating unit. Unfortunately, the number of flavour compounds, which can be studied with this method, is limited due to their low water solubility and their low UV absorption.

Aqueous solutionChromatographyPyrazineChemistryHydrogen bond[SDV]Life Sciences [q-bio]FlavourGel permeation chromatography[SDV] Life Sciences [q-bio]chemistry.chemical_compoundPOLYSACCHARIDEPolymerizationOrganic chemistryThiazoleComputingMilieux_MISCELLANEOUSFlavorFood Science
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct